Literature DB >> 25229141

pH Alters PEG-mediated fusion of phosphatidylethanolamine-containing vesicles.

Hirak Chakraborty1, Tanusree Sengupta1, Barry R Lentz2.   

Abstract

Here, we examine the different mechanisms of poly(ethylene glycol)-mediated fusion of small unilamellar vesicles composed of dioleoylphosphatidylcholine/dioleoylphosphatidylethanolamine (DOPE)/sphingomyelin/cholesterol in a molar ratio of 35:30:15:20 at pH 7.4 versus pH 5. In doing so, we test the hypothesis that fusion of this lipid mixture should be influenced by differences in hydration of DOPE at these two pH values. An examination of the literature reveals that DOPE should be less hydrated at pH 5 (where influenza virus particles fuse with endosome membranes) than at pH 7.4 (where synaptic vesicles or HIV virus particles fuse with plasma membrane). Ensemble kinetic experiments revealed substantial differences in fusion of this plasma membrane mimetic system at these two pH values. The most dramatic difference was the observation of two intermediates at pH 5 but loss of one of these fusion intermediates at pH 7.4. Analysis of data collected at several temperatures also revealed that formation of the initial fusion intermediate (stalk) was favored at pH 7.4 due to increased activation entropy. Our observations support the hypothesis that the different negative intrinsic curvature of DOPE can account for different fusion paths and activation thermodynamics in steps of the fusion process at these two pH values. Finally, the effects of 2 mol % hexadecane on fusion at both pH values seemed to have similar origins for step 1 (promotion of acyl chain or hydrocarbon excursion into interbilayer space) and step 3 (reduction of interstice energy leading to expansion to a critical stalk radius). Different hexadecane effects on activation thermodynamics at these two pH values can also be related to altered DOPE hydration. The results support our kinetic model for fusion and offer insight into the critical role of phosphatidylethanolamine in fusion.
Copyright © 2014 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25229141      PMCID: PMC4167301          DOI: 10.1016/j.bpj.2014.07.048

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  37 in total

1.  Studies on the biosynthesis of cholesterol. III. Purification of C14-cholesterol from perfusions of livers and other organs.

Authors:  E SCHWENK; N T WERTHESSEN
Journal:  Arch Biochem Biophys       Date:  1952-10       Impact factor: 4.013

2.  Field theoretic study of bilayer membrane fusion: II. Mechanism of a stalk-hole complex.

Authors:  K Katsov; M Müller; M Schick
Journal:  Biophys J       Date:  2005-11-04       Impact factor: 4.033

3.  Multiple intermediates in SNARE-induced membrane fusion.

Authors:  Tae-Young Yoon; Burak Okumus; Fan Zhang; Yeon-Kyun Shin; Taekjip Ha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-13       Impact factor: 11.205

4.  Calculation of free energy barriers to the fusion of small vesicles.

Authors:  J Y Lee; M Schick
Journal:  Biophys J       Date:  2007-11-16       Impact factor: 4.033

5.  The modified stalk mechanism of lamellar/inverted phase transitions and its implications for membrane fusion.

Authors:  D P Siegel
Journal:  Biophys J       Date:  1999-01       Impact factor: 4.033

6.  In vitro system capable of differentiating fast Ca2+-triggered content mixing from lipid exchange for mechanistic studies of neurotransmitter release.

Authors:  Minjoung Kyoung; Ankita Srivastava; Yunxiang Zhang; Jiajie Diao; Marija Vrljic; Patricia Grob; Eva Nogales; Steven Chu; Axel T Brunger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-24       Impact factor: 11.205

7.  Molecular dynamics simulations of lipid vesicle fusion in atomic detail.

Authors:  Volker Knecht; Siewert-Jan Marrink
Journal:  Biophys J       Date:  2007-03-23       Impact factor: 4.033

8.  Solvent-exposed tails as prestalk transition states for membrane fusion at low hydration.

Authors:  Yuliya G Smirnova; Siewert-Jan Marrink; Reinhard Lipowsky; Volker Knecht
Journal:  J Am Chem Soc       Date:  2010-05-19       Impact factor: 15.419

9.  Atomic-resolution simulations predict a transition state for vesicle fusion defined by contact of a few lipid tails.

Authors:  Peter M Kasson; Erik Lindahl; Vijay S Pande
Journal:  PLoS Comput Biol       Date:  2010-06-24       Impact factor: 4.475

10.  Analysis of membrane fusion as a two-state sequential process: evaluation of the stalk model.

Authors:  Gabriel Weinreb; Barry R Lentz
Journal:  Biophys J       Date:  2007-03-16       Impact factor: 4.033

View more
  5 in total

1.  The Interaction between Influenza HA Fusion Peptide and Transmembrane Domain Affects Membrane Structure.

Authors:  Alex L Lai; Jack H Freed
Journal:  Biophys J       Date:  2015-12-15       Impact factor: 4.033

2.  The transmembrane domain peptide of vesicular stomatitis virus promotes both intermediate and pore formation during PEG-mediated vesicle fusion.

Authors:  Tanusree Sengupta; Hirak Chakraborty; Barry R Lentz
Journal:  Biophys J       Date:  2014-09-16       Impact factor: 4.033

3.  Phosphatidylserine-Dependent Catalysis of Stalk and Pore Formation by Synaptobrevin JMR-TMD Peptide.

Authors:  Pradip K Tarafdar; Hirak Chakraborty; Michael J Bruno; Barry R Lentz
Journal:  Biophys J       Date:  2015-11-03       Impact factor: 4.033

Review 4.  Mechanism of Membrane Fusion: Interplay of Lipid and Peptide.

Authors:  Ankita Joardar; Gourab Prasad Pattnaik; Hirak Chakraborty
Journal:  J Membr Biol       Date:  2022-04-18       Impact factor: 2.426

5.  Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models.

Authors:  Chunlei Guo; Yanan Chen; Wenjuan Gao; Antao Chang; Yujie Ye; Wenzhi Shen; Yunping Luo; Shengyong Yang; Peiqing Sun; Rong Xiang; Na Li
Journal:  Theranostics       Date:  2017-01-26       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.